RSV Fusion-Blocking Peptides for Low-Cost Antiviral Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective, low-cost antiviral agents for respiratory syncytial virus (RSV) infections, with existing treatments like Palivizumab being costly and limited in availability, and no vaccine or therapeutic approach currently available.
Innovation Solution
Development of short synthetic peptides targeting the prefusion conformation of the RSV fusion protein, which can be conjugated to nucleic acid nanostructures to enhance binding efficacy, preventing the fusion of RSV with host cell membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies like Palivizumab are used to treat RSV infections, then antiviral efficacy is achieved, but cost and availability become limiting factors
Solution Approach 1:
The patent creates simplified peptide copies that mimic the binding function of full-length monoclonal antibodies. These peptides replicate the essential antiviral activity by targeting the same epitope on the RSV fusion protein, but with reduced structural complexity that enables more economical production and broader availability while maintaining therapeutic efficacy
Solution Approach 2:
The invention extracts the critical functional domain from the complete monoclonal antibody structure. By isolating and synthesizing only the essential peptide sequence required for viral binding and inhibition, the patent eliminates unnecessary structural elements, thereby reducing manufacturing costs and simplifying production processes while preserving the core antiviral mechanism
2Ease of manufacture
If short synthetic peptides are used instead of monoclonal antibodies, then cost is reduced, but binding efficacy may be compromised
Solution Approach 1:
The patent systematically optimizes peptide parameters including amino acid sequence, length, and structural conformation to maximize binding affinity for the RSV fusion protein. By carefully adjusting these parameters and selecting specific epitope targets, the invention achieves high binding efficacy despite the reduced size of synthetic peptides compared to full-length monoclonal antibodies
Solution Approach 2:
The invention employs composite peptide structures that combine multiple functional elements within a single synthesized sequence. These composite peptides integrate viral binding domains with stabilizing structural motifs, creating molecules that achieve both cost-effectiveness through synthetic simplicity and high binding efficacy through optimized multi-functional design
3Reliability
If peptides target the prefusion conformation of RSV fusion protein, then viral entry is blocked, but the transient nature of prefusion conformation makes targeting difficult
Solution Approach 1:
The patent designs peptides that proactively bind to the prefusion conformation of the RSV fusion protein before viral entry can occur. By creating high-affinity peptides that stabilize the prefusion state and prevent conformational changes necessary for fusion, the invention blocks viral entry at the earliest possible stage, addressing the transient nature of the target through preemptive binding
Solution Approach 2:
The invention introduces synthetic peptides as intermediary molecules that mediate between the host cell and the RSV virus. These peptide intermediaries bind to the fusion protein and prevent direct virus-cell membrane interaction, simplifying the targeting challenge by creating a stable intermediate complex that blocks the viral entry pathway without requiring direct modification of the transient prefusion conformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate in vitro and in vivo efficacy in reducing viral load and inhibiting RSV entry and spread, offering a cost-effective alternative to monoclonal antibodies with reduced side-effects and improved stability.
Implementation Method 1
peptides targeting the prefusion conformation of the RSV fusion protein... preventing the fusion of RSV with host cell membranes
Data Source
AI summary
The present invention relates to a peptide with a length of 25 amino acids or less comprising the sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13 (SEQ ID No: 1) as well as to A peptide with a length of 25 amino acids or less comprising the sequence X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (SEQ ID No: 2). The present invention further relates to a nanostructure comprising a nucleic acid scaffold and at least two peptide moieties, wherein the sequence of each of the at least two peptide moieties is independently selected from the sequence of the peptide of the invention as well as pharmaceutical compositions, nucleic acids, methods and uses related thereto.